The triple action creates synergy
The Fund may be susceptible to an increased risk of loss, including losses due to adverse events that affect the Funds investments more than the market as a whole, to the extent that the Funds investments are concentrated in the securities and/or other assets of a particular issuer or issuers, country, group of countries, region, market, industry, group of industries, sector, market segment or asset class
If you have concerns about any medical test or procedure, discuss these with your GP or prescribing clinician, who can provide personalised advice based on your individual circumstances

Related products Add to cartQuick ViewWellness and Vitality Trace stress x *60 tablets 15,000.00 0 out of 5 Add to cartQuick ViewWellness and Vitality Earth Creation 21 Again Anti-aging Formula *60 capsules 38,000.00 0 out of 5 Add to cartQuick ViewWellness and Vitality Reload mens Formula *30 tablets 19,500.00 0 out of 5 Add to cartQuick ViewWellness and Vitality Itex Chaste Tree(400mg)*100 capsules 18,500.00 0 out of 5 Add to cartQuick ViewWellness and Vitality Beehive Botanicals Royal jelly *100 capsules 16,500.00 0 out of 5 Add to cartQuick ViewWellness and Vitality Purtains Pride cranberry Gummies*150 Gummies 24,500.00 0 out of 5 Add to cartQuick ViewWellness and Vitality Medson &Grocer Oculo-f *120 softgels 34,000.00 0 out of 5 Add to cartQuick ViewWellness and Vitality Nutravit Nutra Flow *30 tablets 15,000.00 0 out of 5 Best Selling Products Refire *10 capsules5,000.00 0 out of 5 Potassium 0 out of 5 Myo -Inositol *120 capsules58,000.00 0 out of 5 Latest Products Pure Evening Primrose Oil 0 out of 5 Collagen & Biotin 0 out of 5 Vitamin B-12 0 out of 5 Top Rated products Refire *10 capsules5,000.00 0 out of 5 Potassium 0 out of 5 Myo -Inositol *120 capsules58,000.00 0 out of 5

We look forward to working with regulators as they evaluate this first-of-its-kind medicine." In TRIUMPH-2, all three studied doses of retatrutide (4 mg, 9 mg, and 12 mg) delivered substantial weight loss and improved glycemic control at 80 weeks in adults with type 2 diabetes and obesity or overweight